Global Acromegaly Drugs Market 2021-2027

Description

List of Tables

Global Acromegaly Drug Market Size, Share & Trends Analysis Report by Product Type (Somatostatin Analogs, Growth Hormone Receptor Antagonist (GHRA), Dopamine Agonists, and Other Product Types), Forecast Period (2021-2027)

The global acromegaly drug market is anticipated to grow at a considerable CAGR during the forecast period. Acromegaly is a hormonal condition that occurs when the pituitary gland produces too much growth hormone in maturity. According to the National Institutes of Health (NIH) and Endocrine Society, around 69,000 individuals living with acromegaly globally. In addition, increasing incidence of pituitary tumors and acromegaly, changing lifestyle and increasing investments in R&D for developing new molecules are driving the growth of acromegaly drugs market.

The global acromegaly drugs market is segmented based on product type into somatostatin analogs, growth hormone receptor antagonist (GHRA), dopamine agonists, and other product types. Somatostatin analogs segment is estimated to hold a prominent share in the acromegaly drugs market and is anticipated to show a similar trend during the forecast period owing to the wide availability of drugs and its cost-efficiency.

Geographically, the global acromegaly drugs market covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and the Rest of the World.

Market Segmentation

1. Global Acromegaly Drugs Market Research and Analysis by Product Type

The Report Covers

Comprehensive research methodology of the global acromegaly drugs market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global acromegaly drugs market.
Insights about market determinants that are stimulating the global acromegaly drugs market.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: OMR2024112

1. Report Summary

1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Conclusion

3. Market Determinants

3.1. Motivators
3.2. Restraints
3.3. Opportunities

4. Market Segmentation

4.1. Global Acromegaly Drug Market by Product Type
- 4.1.1. Somatostatin Analogs
- 4.1.2. Growth Hormone Receptor Antagonist (GHRA)
- 4.1.3. Dopamine Agonists
- 4.1.4. Other Product Types

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. Chiasma Inc.
6.2. Ionis Pharmaceuticals Inc.
6.3. Ipsen
6.4. Novartis AG
6.5. Pfizer Inc
6.6. Validus Pharmaceuticals LLC